BRAF and melanoma: Aberrant signaling or hyper activation of MAPK pathway has been shown in many tumors including melanomas, non-small cell lung cancer (NSCLC), pancreatic and colorectal cancers, chiefly due to mutations in RAS and BRAF proto-oncogenes (22).